Studies
The iCARUS Research Portfolio
CURRENT STUDIES
MATTER is a randomized controlled trial examining whether evidence-informed psychobehavioral intervention mitigates the negative behavioral impact of internalized stigmas and shame on viral suppression among people living with HIV and substance use disorders (SUDs).
TRIDENT is a randomized controlled trial examining whether and how depression treatment modifies the gut-brain axis in people with HIV.
The reSTART study is testing the effectiveness of reSTART, which integrates a novel POC
urine adherence test for optimizing viral suppression and an mHealth application to reduce stimulant use
AMETHST is a national cohort of HIV-negative sexual minority men examining whether methamphetamine use alters rectal immune function. It is a randomized controlled trial aimed at increasing the use of pre-exposure prophylaxis.
NeuroARTEMIS is a randomized controlled trial that is assessing an evidence-based positive affect intervention (ARTEMIS) as a mechanistic probe to elucidate the neural and immunologic substrates linking psychosocial stress to substance use and depression in PWH.
ARCHES is a national cohort study to identify the multi-level determinants that modify the associations of stimulant use with viral suppression and inflammation among sexual minority men with HIV.
ARES is a 6-month, prospective cohort study assessing whether the use of methamphetamine triggers activation of the viral reservoir and may correlate with an increase in HIV clinical disease markers.
The START study was a randomized controlled trial that tested whether an app to optimize HIV treatment as prevention in sexual minority men living with HIV who use stimulants.
PrEP-to-Bay was a pilot randomized controlled trial testing a motivational interviewing intervention to increase PrEP adherence in young sexual minority men with syndemic comorbidities.
PAST STUDIES
The MyTPill study used a counterbalanced design to determine the differential validity of two electronic adherence monitoring strategies in people with HIV who use opioids or stimulants.
TITAN is a randomized controlled trial testing novel, trauma-informed care approaches for Cambodian people with Post-Traumatic Stress Disorder (PTSD).
The CRUSH study aimed to understand how COVID, HIV, and methamphetamine use impact sexual minority men.
PRISM 2.0 was a pilot sequential multiple assignment randomized controlled trial testing motivational enhancement interventions to increase PrEP use in sexual minority men who use stimulants.
PRISM 1.0 was a biobehavioral study conducted in the STI clinic setting to examine correlates of rectal immune function and the rectal microbiome.
PARTI was a randomized controlled trial that tested a positive affect intervention to increase PrEP adherence among sexual minority men who use stimulants.
ARTEMIS was a randomized controlled trial that demonstrated a positive affect intervention delivered during CM for stimulant abstinence achieved durable viral suppression in sexual minority men with HIV who use methamphetamine.